Results of 68Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1

Sadowski, Samira M.; Millo, Corina; Cottle‐Delisle, Candice; Merkel, Roxanne; Yang, Liangcheng; Herscovitch, Peter; Pacák, Karel; Simonds, William F.; Marx, Stephen J.; Kebebew, Electron

doi:10.1016/j.jamcollsurg.2015.04.005

Cited by 76 publications

(78 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…68 Ga-DOTATATE scans were performed in 10 patients as previously described 13,14 . Five mCi of 68 Ga-DOTATATE was administered through a peripheral vein.…”

Section: Methodsmentioning

confidence: 99%

Localization of Insulinoma Using 68Ga-DOTATATE PET/CT Scan

Nockel

Babic

Millo

et al. 2016

The Journal of Clinical Endocrinology &Amp; Metabolism

Self Cite

View full text Add to dashboard Cite

Context. The reliable localization of insulinoma is critical for the successful surgical treatment.Objective. This study compared the accuracy of 68 Gallium (Ga)-DOTATATE PET/CT to anatomic imaging modalities, selective arterial secretagogue injection (SASI), and intraoperative ultrasound (IOUS) and palpation for localizing insulinoma in patients who were biochemically cured. Design, Setting, and Patients. We conducted a retrospective analysis of 31 patients who had an insulinoma confirmed on histology and were biochemically cured. The results of CT, MRI, transabdominal US, IOUS, 68 Ga-DOTATATE PET/CT, SASI, and operative findings were analyzed. Intervention, Main Outcome Measures, Results: The insulinomas were correctly localized in 17 out of 31 (55%) of patients by CT, in 17 out of 28 (61%) by MRI, in 6 out of 28 (21%) by US, and in 9 out of 10 (90%) by 68 Ga-DOTATATE. IOUS was performed in 31 patients, and 29 of them had an insulinoma successfully localized (93.5%). Thirty patients underwent SASI, and the insulinoma was regionalized in 28 out of 30 patients (93%). In 19 out of 23 patients (83%), manual palpation identified insulinoma. In patients who had all four noninvasive imaging studies, CT was concordant with 68 Ga-DOTATATE in 6 out of 9 patients (67%); MRI in 8 out of 9 (78%); US in 0 out of 9; and in 1 out of 9 patients (11%) the lesion was only seen by 68 Ga-DOTATATE. Conclusions:68 Ga-DOTATATE PET/CT identifies most insulinomas and may be considered as an adjunct imaging study when all imaging studies are negative and when a minimally invasive surgical approach is planned.PRECIS: We studied 68Ga-DOTATATE PET/CT imaging in patients with insulinoma and found it identifies most tumors and should be considered as an adjunct imaging study.

show abstract

“…68 Ga-DOTATATE scans were performed in 10 patients as previously described 13,14 . Five mCi of 68 Ga-DOTATATE was administered through a peripheral vein.…”

Section: Methodsmentioning

confidence: 99%

Localization of Insulinoma Using 68Ga-DOTATATE PET/CT Scan

Nockel

Babic

Millo

et al. 2016

The Journal of Clinical Endocrinology &Amp; Metabolism

Self Cite

View full text Add to dashboard Cite

show abstract

“…68 Ga-DOTATOC detected 46 pancreatic tumors, 111 In-pentetreotide detected 11, and contrast-enhanced CT detected 37. In a prospective study evaluating 68 Ga-DOTATATE versus 111 In-pentetreotide and contrast-enhanced CT in 26 patients with multiple endocrine neoplasia type 1, 68 Ga-DOTATATE PET/CT detected 107 lesions, 111 In-pentetreotide SPECT/CT detected 33 lesions, and CT detected 48 lesions (30). In 8 of the 26 patients (31%), there was a change in management recommendations as a result of findings on 68 Ga-DOTATATE PET/CT that were not seen on 111 In-pentetreotide SPECT/CT or CT.…”

Section: Radiolabeled Somatostatin Analogsmentioning

confidence: 99%

Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions

et al. 2016

Self Cite

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to (1) summarize the main clinical features of gastroenteropancreatic neuroendocrine tumors; (2) describe the specific mechanisms of uptake of radiotracers and identify the relation of imaging phenotype with site of origin and tumor grade; and (3) recommend the best imaging modalities across the different tumor subtypes for imaging and for selecting candidates for peptide receptor radionuclide therapy.

show abstract

“…The Ga-68 DOTATATE scans were performed as previously described (9,10). Five mCi of Ga-68 DOTATATE was administered through a peripheral vein.…”

Section: Evaluation and Analysis Of Thyroid Uptake As Detected By Ga-mentioning

confidence: 99%

The Rate and Clinical Significance of Incidental Thyroid Uptake as Detected by Gallium-68 DOTATATE Positron Emission Tomography/Computed Tomography

Nockel

Millo

Keutgen

et al. 2016

Thyroid

Self Cite

View full text Add to dashboard Cite

Gallium-68 (Ga-68) DOTATATE is a radiolabeled peptide-imaging modality that targets the somatostatin receptor (SSTR), especially subtype 2 (SSTR2). Benign and malignant thyroid tumors have been observed to express SSTR. The aim of this study was to evaluate the frequency and clinical significance of incidental atypical thyroid uptake as detected by Ga-68 DOTATATE positron emission tomography/computed tomography (PET/CT)

show abstract

Results of 68Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1

Cited by 76 publications

References 27 publications

Localization of Insulinoma Using 68Ga-DOTATATE PET/CT Scan

Localization of Insulinoma Using 68Ga-DOTATATE PET/CT Scan

Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions

The Rate and Clinical Significance of Incidental Thyroid Uptake as Detected by Gallium-68 DOTATATE Positron Emission Tomography/Computed Tomography

Contact Info

Product

Resources

About